Lee Hambright
Stock Analyst at Bernstein
(4.24)
# 459
Out of 4,996 analysts
26
Total ratings
80%
Success rate
10.61%
Average return
Main Sectors:
Stocks Rated by Lee Hambright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Outperform | $97 → $98 | $94.22 | +4.01% | 3 | Aug 20, 2025 | |
| ABT Abbott Laboratories | Maintains: Outperform | $138 → $144 | $133.55 | +7.82% | 5 | Apr 17, 2025 | |
| PODD Insulet | Initiates: Outperform | $300 | $318.00 | -5.66% | 1 | Nov 6, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Outperform | $42 | $12.00 | +250.00% | 1 | Nov 6, 2024 | |
| DXCM DexCom | Maintains: Outperform | $82 → $86 | $67.10 | +28.17% | 2 | Oct 25, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $92 → $100 | $98.18 | +1.85% | 1 | Oct 24, 2024 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $350 → $365 | $441.12 | -17.26% | 2 | May 31, 2023 | |
| ZBH Zimmer Biomet Holdings | Maintains: Market Perform | $136 → $152 | $98.24 | +54.72% | 1 | May 3, 2023 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $183 | $179.71 | +1.83% | 4 | Mar 16, 2022 | |
| SYK Stryker | Upgrades: Outperform | $288 → $295 | $369.02 | -20.06% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $132 → $135 | $76.25 | +77.05% | 3 | Mar 16, 2022 |
Medtronic
Aug 20, 2025
Maintains: Outperform
Price Target: $97 → $98
Current: $94.22
Upside: +4.01%
Abbott Laboratories
Apr 17, 2025
Maintains: Outperform
Price Target: $138 → $144
Current: $133.55
Upside: +7.82%
Insulet
Nov 6, 2024
Initiates: Outperform
Price Target: $300
Current: $318.00
Upside: -5.66%
Tandem Diabetes Care
Nov 6, 2024
Initiates: Outperform
Price Target: $42
Current: $12.00
Upside: +250.00%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $82 → $86
Current: $67.10
Upside: +28.17%
Boston Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $92 → $100
Current: $98.18
Upside: +1.85%
Intuitive Surgical
May 31, 2023
Maintains: Outperform
Price Target: $350 → $365
Current: $441.12
Upside: -17.26%
Zimmer Biomet Holdings
May 3, 2023
Maintains: Market Perform
Price Target: $136 → $152
Current: $98.24
Upside: +54.72%
Johnson & Johnson
Mar 16, 2022
Downgrades: Market Perform
Price Target: $183
Current: $179.71
Upside: +1.83%
Stryker
Mar 16, 2022
Upgrades: Outperform
Price Target: $288 → $295
Current: $369.02
Upside: -20.06%
Mar 16, 2022
Upgrades: Outperform
Price Target: $132 → $135
Current: $76.25
Upside: +77.05%